AbbVie (NYSE: ABBV) announced global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Read More »

These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein (hsCRP) levels, and persistent high triglycerides (TG) despite statin therapy due to the association with increased cardiovascular disease (CVD) risk. Read More »

Acorda Therapeutics, Inc. will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Read More »

As part of Aetna’s commitment to enhancing access to evidence-based addiction treatment options for its members, medication-assisted treatment (MAT) is available for those with opioid use disorder. Read More »

A research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43rdAnnual Health Care Conference on Wednesday, May 9, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time. Read More »

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility. Additionally, the presentation highlights recently announced opportunities, including: Read More »

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the House Energy and Commerce Health Subcommittee’s hearing Combating the Opioid Crisis: Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has acquired global development and marketing rights from Prayog Labs LLC to bring to market a fast-acting Meloxicam as a proposed non-narcotic analgesic. Read More »

Just announced that John Renger, Ph.D., has been appointed Vice President, Head of Research & Development and Regulatory Affairs. He will be based in Stamford, Connecticut and report directly to President and CEO Craig Landau, MD. Read More »

As the independent drugstore lobby descends on Capitol Hill this week to push for costly new government health mandates, the Pharmaceutical Care Management Association (PCMA) continues to highlight how pharmacy benefit managers (PBMs) reduce prescription drug costs and improve benefits for consumers, employers, unions, and public programs. Read More »

ASHP, in collaboration with the Pediatric Pharmacy Advocacy Group (PPAG), today published updated national guidelines outlining best practices for pediatric pharmacy care in hospitals and health systems. Read More »

Afinitor DISPERZ (everolimus) is first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Read More »

One of the world's leading pharmaceutical companies, and Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, today announced that the two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product. Read More »

Report from Orexo AB’s annual general meeting Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics. Through the partnership agreement, Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe. Read More »

Imagine having a chronic disease that affects almost every organ in your body and can lead to intense, debilitating pain episodes that often send you to the ER.1,2 What’s more, there are generally no warning signs, making it difficult to not only plan ahead for special events, but to keep up with the day-to-day activities most people take for granted. Too often, this is a recurring cycle for people with sickle cell disease (SCD). Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billion aggregate principal amount of senior notes on March 28, 2018 Read More »

Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. Read More »

The annual Harvey A.K. Whitney Lecture Award recognizes individuals who have made outstanding contributions to health-system pharmacy. The award is considered to be the highest honor in the profession. Read More »